Lupin Share Price Today

Lupin gets US FDA approval for Phytonadione injectable emulsion

Lupin secured US FDA approval for Phytonadione Injectable Emulsion USP. The product is a 1 mg/0.5 mL single-dose prefilled syringe. The target market has estimated annual sales of $52.3 million in the U.S. Approval confirms bioequivalence to International Medication Systems' RLD.

Lupin launches world's first triple-combination COPD drug in India

Lupin launched Formoflo-G MDI, the world's first fixed-dose triple combination inhaler for COPD in India. The drug combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate. Approval granted by the Drug Controller General of India (DCGI) for moderate to severe COPD management. Lupin ranks #2 in India's respiratory therapy segment per IQVIA MAT Mar 2026 data. The launch targets over 55 million people living with COPD in India.

Lupin subsidiary completes buyback, becomes wholly owned entity

Lupin Ltd subsidiary Multicare Pharmaceuticals Philippines completed buyback of 30,559 shares. Effective October 1, 2026, MPPI became wholly owned subsidiary of Nanomi B.V. Transaction follows earlier intimation dated July 1, 2026. Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015.

Lupin receives tentative FDA approval for novel apixaban oral suspension

Lupin received tentative FDA approval for Apixaban Oral Suspension 1.25mg/mL on September 28, 2026. The product was approved via the 505(b)(2) regulatory pathway as a liquid alternative to tablets. Manufacturing will occur at Lupin's facility in Somerset, New Jersey upon final approval.

Lupin to attend Kotak, J.P. Morgan investor meets in September

Lupin will attend the Kotak Healthcare Conference on September 17, 2026. The company is also scheduled for a group meet at the J.P. Morgan India Conference on September 21. Both events are in-person group meetings with analysts and institutional investors. Presentations will follow content already available on exchange websites.

Lupin receives US FDA approval for Modafinil Tablets

Lupin receives US FDA approval for Modafinil Tablets. Product is a wakefulness-promoting agent for narcolepsy. Approval expands Lupin's portfolio in the US market.